Related Experiment Video

Updated: Apr 12, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia

Rutger Verbeek1, Robert M Stoekenbroek2, G Kees Hovingh1

  • 1Department of Vascular Medicine, Academic Medical Center, PO box 22660, 1100 DD Amsterdam, the Netherlands.

European Journal of Pharmacology
|May 20, 2015
PubMed

Insights

New PCSK9 inhibitors significantly lower LDL cholesterol, offering hope for patients unresponsive to current treatments. These therapies aim to reduce cardiovascular disease risk by targeting PCSK9 pathways.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pharmacology

Background:

  • Lowering low-density lipoprotein cholesterol (LDL-c) is crucial for cardiovascular disease (CVD) prevention.
  • Many patients do not achieve target LDL-c levels with existing therapies.
  • Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibition is a novel therapeutic strategy.

Purpose of the Study:

  • To evaluate PCSK9 inhibition as a strategy to reduce residual CVD risk.
  • To assess the efficacy of PCSK9 inhibition in lowering LDL-c levels.
  • To investigate the potential of PCSK9 inhibitors in clinical practice.

Main Methods:

  • Development of approaches to target PCSK9, including monoclonal antibodies.
  • Evaluation of three PCSK9 monoclonal antibodies in phase 3 clinical trials.
  • Assessment of LDL-c reductions in diverse patient populations on various lipid-lowering therapies.

Main Results:

  • PCSK9 inhibition demonstrated LDL-c reductions of up to 70%.
  • Efficacy was observed independently of background statin therapy.
  • Monoclonal antibodies targeting PCSK9 are in late-stage clinical development.

Conclusions:

  • PCSK9 inhibition represents a promising therapeutic avenue for managing hyperlipidemia.
  • Phase 3 trial results are anticipated to confirm long-term efficacy and safety.
  • The translation of LDL-c lowering to improved CVD outcomes requires further investigation.

Keywords:
AlirocumabBococizumabEvolocumabPCSK9Proprotein Convertase Subtilisin/Kexin type 9

More Related Videos

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK908:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
602
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
91
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
764
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
615
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
421